Company news
Harrow, Inc. news in 2022
Harrow, Inc.'s news releases, calls and decks from 2022, newest first.
Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study
December 20, 2022
Harrow Secures Capital to Close Recently Announced Acquisition
December 15, 2022
Harrow Prices $25 Million Offering
December 13, 2022
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®
December 13, 2022
Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones
December 13, 2022
Harrow and iOR Partners Expand National Product Supply Agreement
November 29, 2022
Harrow Announces Third Quarter 2022 Financial Results
November 13, 2022
Harrow Launches Atropine.com
November 9, 2022
Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
October 27, 2022
Harrow Sells Non-Ophthalmic Compounding Business
October 4, 2022
ImprimisRx Launches Fortisite™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation
September 28, 2022
Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia
September 26, 2022
Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 10, 2022
Harrow Health Announces Second Quarter 2022 Financial Results
August 8, 2022
Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022
July 26, 2022
Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States
June 23, 2022
Harrow Health Announces First Quarter 2022 Financial Results
May 4, 2022
Harrow Health to Participate in B. Riley Securities’ Annual Neuro & Ophthalmology Investor Conference
April 21, 2022
Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022
April 19, 2022
Harrow Health Announces Appointments to Its Board of Directors
March 30, 2022
Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results
March 9, 2022
Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022
February 23, 2022
Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100
February 21, 2022
Harrow Health to Present at Aegis Virtual Conference
February 14, 2022
Harrow Health Publishes Corporate Transparency Report
February 7, 2022
Harrow Health to Participate in H.C. Wainwright BioConnect Conference
January 9, 2022
Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA
January 3, 2022
Calls in 2022
Decks in 2022
- Harrow Health — Investor Presentation (August 2022)
Investor deck · 10 slides · August 2022
- Harrow Health — Investor Presentation (May 2022)
Investor deck · 10 slides · May 2022
- Harrow Health — Investor Presentation (January 2022)
Investor deck · 13 slides · Jan 10, 2022